Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Relugolix, estradiol hemihydrate, and norethindrone acetate

Drug class: Gonadotropin Releasing Hormone Receptor Antagonist

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Relugolix, estradiol hemihydrate, and norethindrone acetate key facts

Drug class
Gonadotropin Releasing Hormone Receptor Antagonist
Used for
MYFEMBREE is a combination of relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin, indicated in premenopausal women for the: management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids). (source)
Prescription or over the counter
Prescription (Rx)
Generic available
No generic listed by the FDA
Typical pharmacy cost
$45.25 per tablet (estradiol hemihydrate 1 mg · norethindrone acetate 0.5 mg · relugolix 40 mg; NADAC)
Latest FDA recall
None listed

Sources: FDA label (October 27, 2026); FDA NDC Directory (November 13, 2026); CMS NADAC (November 11, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Relugolix, estradiol hemihydrate, and norethindrone acetate used for?
The FDA-approved label (Myfembree, Sumitomo Pharma America, Inc, October 27, 2026) says: “MYFEMBREE is a combination of relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin, indicated in premenopausal women for the: management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids). ( 1.1, 14.1 ) management of moderate to severe pain associated with endometriosis. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Relugolix, estradiol hemihydrate, and norethindrone acetate?
The “Adverse Reactions” section of the FDA label (Myfembree, Sumitomo Pharma America, Inc, October 27, 2026) begins: “The following clinically significant adverse reactions are discussed elsewhere in the labeling: Thromboembolic Disorders and Vascular Events [see Warnings and Precautions (5.1)] Bone Loss [see Warnings and Precautions (5.2)] Suicidal Ideation and Mood Disorders (Including Depression) [see Warnings and Precautions (5.4)] Hepatic Impairment and Transaminase Elevations [see Warnings and Precautions (5.5)] Elevated Blood Pressure [see Warnings and Precautions (5.7)] Change in …” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Relugolix, estradiol hemihydrate, and norethindrone acetate?
The “Drug Interactions” section of the FDA label (Myfembree, Sumitomo Pharma America, Inc, October 27, 2026) begins: “Avoid use of MYFEMBREE with oral P-gp inhibitors. (7.1) Avoid use with combined P-gp and strong CYP3A inducers, as the exposure of the components of MYFEMBREE may be decreased. (7.1) 7.1 Effect of Other Drugs on MYFEMBREE P-gp Inhibitors Co-administration of MYFEMBREE with P-gp inhibitors increases the AUC and maximum concentration (C max) of relugolix [see Clinical Pharmacology (12.3)] and may increase the risk of adverse reactions associated with MYFEMBREE.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Relugolix, estradiol hemihydrate, and norethindrone acetate have a boxed warning?
Yes. The FDA label for Myfembree has a boxed warning (“WARNING: THROMBOEMBOLIC DISORDERS AND VASCULAR”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
Is there a shortage of Relugolix, estradiol hemihydrate, and norethindrone acetate?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Relugolix, estradiol hemihydrate, and norethindrone acetate been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Relugolix, estradiol hemihydrate, and norethindrone acetate?
1 company lists prescription products of Relugolix, estradiol hemihydrate, and norethindrone acetate in the FDA NDC Directory, including Sumitomo Pharma America, Inc.

What Relugolix, estradiol hemihydrate, and norethindrone acetate is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

MYFEMBREE is a combination of relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin, indicated in premenopausal women for the: management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids). ( 1.1, 14.1 ) management of moderate to severe pain associated with endometriosis. …

— FDA label: Myfembree, Sumitomo Pharma America, Inc, effective October 27, 2026. Read the full label on DailyMed →

Label quoted: the one for the most common form (tablet, film coated, oral), Myfembree, Sumitomo Pharma America, Inc; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

This label has a boxed warning. Its heading: WARNING: THROMBOEMBOLIC DISORDERS AND VASCULAR. Read it on the full label →

Relugolix, estradiol hemihydrate, and norethindrone acetate boxed warning: what the label says

Quoted from the boxed warning of the FDA-approved label.

WARNING: THROMBOEMBOLIC DISORDERS AND VASCULAR Events Estrogen and progestin combinations, including MYFEMBREE, increase the risk of thrombotic or thromboembolic disorders, including pulmonary embolism (PE), deep vein thrombosis (DVT), stroke and myocardial infarction (MI), especially in women at increased risk for these events [see Warnings and Precautions (5.1)] MYFEMBREE is contraindicated in women with current or a history of thrombotic or thromboembolic disorders and in women at increased risk for these events, including women over 35 years of age who smoke or women with uncontrolled hypertension [see Contraindications (4)].

Read more of this section

WARNING: THROMBOEMBOLIC DISORDERS AND VASCULAR EVENTS See full prescribing information for complete boxed warning Estrogen and progestin combinations, including MYFEMBREE, increase the risk of thrombotic or thromboembolic disorders, especially in women at increased risk for these events. (5.1) MYFEMBREE is contraindicated in women with current or a history of thrombotic or thromboembolic disorders and in women at increased risk for these events, including women over 35 years of age who smoke or women with uncontrolled hypertension. (4)

— FDA label: Myfembree, Sumitomo Pharma America, Inc, effective October 27, 2026. Read the full label on DailyMed →

Relugolix, estradiol hemihydrate, and norethindrone acetate side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The following clinically significant adverse reactions are discussed elsewhere in the labeling: Thromboembolic Disorders and Vascular Events [see Warnings and Precautions (5.1)] Bone Loss [see Warnings and Precautions (5.2)] Suicidal Ideation and Mood Disorders (Including Depression) [see Warnings and Precautions (5.4)] Hepatic Impairment and Transaminase Elevations [see Warnings and Precautions (5.5)] Elevated Blood Pressure [see Warnings and Precautions (5.7)] Change in …

— FDA label: Myfembree, Sumitomo Pharma America, Inc, effective October 27, 2026. This is part of the section. Read the full label on DailyMed →

Relugolix, estradiol hemihydrate, and norethindrone acetate drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

Avoid use of MYFEMBREE with oral P-gp inhibitors. (7.1) Avoid use with combined P-gp and strong CYP3A inducers, as the exposure of the components of MYFEMBREE may be decreased. (7.1) 7.1 Effect of Other Drugs on MYFEMBREE P-gp Inhibitors Co-administration of MYFEMBREE with P-gp inhibitors increases the AUC and maximum concentration (C max) of relugolix [see Clinical Pharmacology (12.3)] and may increase the risk of adverse reactions associated with MYFEMBREE.

Read more of this section

Avoid use of MYFEMBREE with oral P-gp inhibitors. If use is unavoidable, take MYFEMBREE first, separate dosing by at least 6 hours, and monitor patients for adverse reactions [see Dosage and Administration (2.4)]. Combined P-gp and Strong CYP3A Inducers Use of MYFEMBREE with combined P-gp and strong CYP3A inducers decreases the AUC and C max of relugolix, estradiol, and/or norethindrone [see Clinical Pharmacology (12.3)] and may decrease the therapeutic effects of MYFEMBREE. Avoid use of MYFEMBREE with combined P-gp and strong CYP3A inducers.

— FDA label: Myfembree, Sumitomo Pharma America, Inc, effective October 27, 2026. Read the full label on DailyMed →

Relugolix, estradiol hemihydrate, and norethindrone acetate dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

Exclude pregnancy and discontinue hormonal contraceptives prior to MYFEMBREE initiation. (2.1) Take one tablet orally once daily. (2.2) Take the missed dose of MYFEMBREE as soon as possible the same day and then resume regular dosing the next day at the usual time.

Read more of this section

(2.3) If concomitant use of oral P-gp inhibitors is unavoidable, take MYFEMBREE at least 6 hours before taking the P-gp inhibitor (2.4) 2.1 Prior to Initiation of MYFEMBREE Exclude pregnancy [see Contraindications (4)]. Discontinue hormonal contraceptives [see Warnings and Precautions (5.8)] 2.2 Recommended Dosage Take one tablet of MYFEMBREE orally once daily at approximately the same time, with or without food [see Clinical Pharmacology (12.3)]. Start MYFEMBREE as early as possible after the onset of menses but no later than seven days after menses has started [see Clinical Studies (14)]. The recommended total duration of treatment with MYFEMBREE is 24 months [see Indications and Usage (1.3), Warnings and Precautions (5.2), and Adverse Reactions (6)]. 2.3 Missed Dose Take the missed dose of MYFEMBREE as soon as possible the same day and then resume regular dosing the next day at the usual time. 2.4 Dosage Modification for Concomitant Use with P-gp Inhibitors Avoid concomitant use of MYFEMBREE with oral P-gp inhibitors. If concomitant use is unavoidable, take MYFEMBREE first and separate dosing by at least 6 hours [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

— FDA label: Myfembree, Sumitomo Pharma America, Inc, effective October 27, 2026. Read the full label on DailyMed →

Relugolix, estradiol hemihydrate, and norethindrone acetate in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Change in Menstrual Bleeding Pattern and Reduced Ability to Recognize Pregnancy Exclude pregnancy before initiating MYFEMBREE [see Dosage and Administration (2.1)]. Start MYFEMBREE as early as possible after the start of menses but no later than 7 days after menses has started. If MYFEMBREE is initiated later in the menstrual cycle, irregular and/or heavy bleeding may initially occur.

Read more of this section

Women who take MYFEMBREE may experience amenorrhea or a reduction in the amount, intensity, or duration of menstrual bleeding, which may delay the ability to recognize pregnancy. Perform pregnancy testing if pregnancy is suspected and discontinue MYFEMBREE if pregnancy is confirmed [see Use in Specific Populations (8.1, 8.3)]. Advise women of reproductive potential to use effective non-hormonal contraception during treatment with MYFEMBREE and for one week after the final dose. Avoid concomitant use of hormonal contraceptives with MYFEMBREE. The use of estrogen-containing hormonal contraceptives can increase estrogen levels which may increase the risk of estrogen-associated adverse events and decrease the efficacy of MYFEMBREE [see Use in Specific Populations (8.1, 8.3)]. 5.9 Risk of Early Pregnancy Loss MYFEMBREE is contraindicated for use in pregnancy [see Contraindications (4)]. Based on findings from animal studies and its mechanism of action, MYFEMBREE can cause early pregnancy loss. However, in both rabbits and rats, no fetal malformations were present at any dose level tested which were associated with relugolix exposures about half and approximately 300 times exposures in women at the recommended human dose [see Use in Specific Populations (8.1)]. 8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to MYFEMBREE during pregnancy. Pregnant females exposed to MYFEMBREE and healthcare providers are encouraged to call the MYFEMBREE Pregnancy Exposure Registry at 1-855-428-0707. Risk Summary MYFEMBREE is contraindicated in pregnancy [see Contraindications (4) and Warnings and Precautions (5.9)]. Based on findings from animal studies and its mechanism of action, MYFEMBREE may cause early pregnancy loss. Discontinue MYFEMBREE if pregnancy occurs during treatment [see Warnings and Precautions (5.9) and Clinical Pharmacology (12.1)]. The limited human data with the use of MYFEMBREE in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes [see Data]. In animal reproduction studies, oral administration of relugolix in pregnant rabbits during organogenesis resulted in spontaneous abortion and total litter loss at relugolix exposures about half those at the maximum recommended human dose (MRHD) of 40 mg. In both rabbits and rats, no fetal malformations were present at any dose level tested which were associated with relugolix exposures about half and approximately 300 times exposures in women at the MRHD, respectively [see Data].

— FDA label: Myfembree, Sumitomo Pharma America, Inc, effective October 27, 2026. This is part of the section. Read the full label on DailyMed →

When Relugolix, estradiol hemihydrate, and norethindrone acetate should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

MYFEMBREE is contraindicated in women: With a high risk of arterial, venous thrombotic, or thromboembolic disorders [see Boxed Warning and Warnings and Precautions (5.1)].

Read more of this section

Examples include women over 35 years of age who smoke and women who are known to have: current or history of deep vein thrombosis or pulmonary embolism vascular disease (e.g., cerebrovascular disease, coronary artery disease, peripheral vascular disease) thrombogenic valvular or thrombogenic rhythm diseases of the heart (e.g., subacute bacterial endocarditis with valvular disease, or atrial fibrillation) inherited or acquired hypercoagulopathies uncontrolled hypertension headaches with focal neurological symptoms or migraine headaches with aura if over 35 years of age Who are pregnant. Exposure to MYFEMBREE early in pregnancy may increase the risk of early pregnancy loss [see Warnings and Precautions (5.9) and Use in Specific Populations (8.1)]. With known osteoporosis, because of the risk of further bone loss [see Warnings and Precautions (5.2)]. With current or history of breast cancer or other hormone-sensitive malignancies, and with increased risk for hormone-sensitive malignancies [see Warnings and Precautions (5.3)]. With known hepatic impairment or disease [see Warnings and Precautions (5.5)]. With undiagnosed abnormal uterine bleeding. With known anaphylactic reaction, angioedema, or hypersensitivity to MYFEMBREE or any of its components. Anaphylactoid reactions, urticaria, and angioedema have been reported [see Warnings and Precautions (5.14), Adverse Reactions (6.2)]. High risk of arterial, venous thrombotic, or thromboembolic disorder. (4) Pregnancy. (4) Known osteoporosis. (4) Current or history of breast cancer or other hormone-sensitive malignancies. (4) Known hepatic impairment or disease. (4) Undiagnosed abnormal uterine bleeding. (4) Known hypersensitivity to components of MYFEMBREE. (4)

— FDA label: Myfembree, Sumitomo Pharma America, Inc, effective October 27, 2026. Read the full label on DailyMed →

Relugolix, estradiol hemihydrate, and norethindrone acetate overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

Overdosage of estrogen plus progestin may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness, fatigue, and withdrawal bleeding. Supportive care is recommended if an overdose occurs. The amount of relugolix, estradiol, or norethindrone removed by hemodialysis is unknown.

— FDA label: Myfembree, Sumitomo Pharma America, Inc, effective October 27, 2026. Read the full label on DailyMed →

Forms and how it is given

Dosage formsTablet, film coated
RouteOral
Prescription products1 in the FDA NDC Directory
Brand namesMyfembree

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Relugolix, estradiol hemihydrate, and norethindrone acetate, by strength and form
Strength and formGeneric or brandPharmacies pay
estradiol hemihydrate 1 mg · norethindrone acetate 0.5 mg · relugolix 40 mg
tablet, film coated
Brand: Myfembree $45.25 per tablet

NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA214846
MYFEMBREE
Sumitomo Pharma AmMay 26, 2021 6, latest August 27, 2025
2025: Labeling · 2024: Labeling · 2024: Efficacy

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)2556799, 2556800
SPL set ID of the quoted labelfc3feb73-cc84-43a8-aa32-b262460495e8
FDA labels (SPL)1
FDA applicationsNDA214846
Active ingredients (FDA)ESTRADIOL HEMIHYDRATE / NORETHINDRONE ACETATE / RELUGOLIX

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Myfembree, Sumitomo Pharma America, Inc, effective October 27, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers